Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developments in laboratory techniques for prenatal diagnosis.

Peter Miny1, Sevgi Tercanli, Wolfgang Holzgreve

  • 1Division of Medical Genetics, University Children's Hospital, Basel, Switzerland.

Current Opinion in Obstetrics & Gynecology
|March 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Update on: Firsttrimester Diagnosis and Therapy @ 11 - 13 <sup>+6</sup> weeks' gestation : Amendment to the Guideline of DEGUM, ÖGUM, SGUMGG, DGGG, ÖGG, Gynecologie Suisse, DGPM, DGPGM, BVF, ACHSE (AWMF S2e LL085-002 1.1.2024) (https://register.awmf.org/de/leitlinien/detail/085-002).

Geburtshilfe und Frauenheilkunde·2025
Same author

Pathogenic variants in SMARCA1 cause an X-linked neurodevelopmental disorder modulated by NURF complex composition.

Nature communications·2025
Same author

Update on: Firsttrimester Diagnosis and Therapy @ 11-13+6 weeks' gestation.

Ultraschall in der Medizin (Stuttgart, Germany : 1980)·2025
Same author

Pathogenic XPO1 variants cause a dominant neurodevelopmental disorder.

Genetics in medicine : official journal of the American College of Medical Genetics·2025
Same author

Bi-allelic loss-of-function variants in POC5 cause a syndromic retinal, endocrine, and neuromuscular ciliopathy.

Genetics in medicine : official journal of the American College of Medical Genetics·2025
Same author

Firsttrimester Diagnosis and Therapy @ 11 - 13 <sup>+6</sup> Weeks of Gestation - Part 2 : Guideline of the DEGUM, ÖGUM, SGUMGG, DGGG, ÖGG, Gynecologie Suisse, DGPM, DGPGM, BVF, ACHSE (AWMF S2e LL 085-002 1.1.2024) (https://register.awmf.org/de/leitlinien/detail/085-002).

Geburtshilfe und Frauenheilkunde·2024
Same journal

Management of hypertensive disorders in pregnancy.

Current opinion in obstetrics & gynecology·2026
Same journal

Updates in group prenatal care research.

Current opinion in obstetrics & gynecology·2026
Same journal

Complex benign gynecology in perimenopause: current evidence and future directions.

Current opinion in obstetrics & gynecology·2026
Same journal

Role of insulin in female reproduction.

Current opinion in obstetrics & gynecology·2026
Same journal

Urinary tract involvement in endometriosis: current evidence and clinical insights into navigating diagnosis and management.

Current opinion in obstetrics & gynecology·2026
Same journal

Updates in ultrasound imaging of adenomyosis and clinical impacts.

Current opinion in obstetrics & gynecology·2026
See all related articles

Prenatal diagnosis advances include rapid, noninvasive methods for aneuploidy screening. New techniques like fluorescence in situ hybridization and PCR analyze fetal DNA from maternal blood for genetic testing.

Area of Science:

  • Reproductive biology
  • Genetics
  • Medical diagnostics

Background:

  • Current prenatal diagnosis focuses on early, rapid, and noninvasive detection of fetal aneuploidy.
  • Established methods include chromosome analysis from chorionic villi.

Purpose of the Study:

  • To review advancements in prenatal diagnostic techniques.
  • To highlight improvements in aneuploidy risk screening and genetic testing.

Main Methods:

  • Interphase-fluorescence in situ hybridization (FISH) and quantitative fluorescence polymerase chain reaction (PCR) for rapid aneuploidy exclusion.
  • Single-cell PCR for monogenic conditions and analysis of fetal DNA/nuclei from maternal plasma for noninvasive diagnosis.
  • Combination of biochemical markers (free beta-hCG, PAPP-A) and sonography for first-trimester risk screening.

Related Experiment Videos

Main Results:

  • FISH and quantitative fluorescence PCR enable rapid exclusion of specific aneuploidies.
  • Single-cell techniques allow genetic diagnosis at the preimplantation stage and potentially from maternal circulation.
  • Noninvasive prenatal testing is enhanced by analyzing fetal DNA in maternal plasma.
  • Combined screening markers significantly improve first-trimester aneuploidy detection sensitivity.

Conclusions:

  • Technological advancements are driving faster, more accurate, and less invasive prenatal genetic testing.
  • Noninvasive methods using maternal plasma components show significant promise for prenatal diagnosis.
  • Integrated screening strategies enhance early detection of fetal chromosomal abnormalities.